

1 **Use of antihypertensive drugs and breast cancer risk: a two-**  
2 **sample Mendelian randomization study**

3 Guoqiao Zheng <sup>1\*</sup>, Subhayan Chattopadhyay <sup>2</sup>, Jan Sundquist <sup>1, 3, 4</sup>, Kristina Sundquist <sup>1, 3, 4</sup>,  
4 Jianguang Ji <sup>1</sup>

5

6 Affiliations of authors:

7 1 Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden

8 2 Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund,  
9 Sweden

10 3 Department of Family Medicine and Community Health, Department of Population Health  
11 Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA

12 4 Center for Community-based Healthcare Research and Education (CoHRE), Department of  
13 Functional Pathology, School of Medicine, Shimane University, Japan

14

15 **\*Correspondence:** Dr. Guoqiao Zheng, Center for Primary Health Care Research, Lund  
16 University/Region Skåne, Jan Waldenströms gata 35, 205 02 Malmö, Sweden.

17 Phone: +46 (40) 39 13 79

18 Email: [guoqiao.zheng@med.lu.se](mailto:guoqiao.zheng@med.lu.se)

19 ORCID: <https://orcid.org/0000-0003-4337-9017>

20

21

22 **Short title:** MR association between antihypertensive drugs and BC risk

23 **Word count:** abstract: 231, main text: 3696

24 **Key words:** antihypertensive medication, cancer risk, causal association, drug repurposing,  
25 adverse drug effect

26

27

## 28 ABSTRACT

### 29 Background

30 Observational studies regarding the correlation between the use of antihypertensive  
31 medication and the risk of breast cancer (BC) reported inconsistent findings. We performed a  
32 two-sample Mendelian randomization using instrumental variables to proxy changes in gene  
33 expressions of antihypertensive medication targets to interrogate this.

### 34 Methods

35 We assessed the association between single-nucleotide polymorphisms (SNPs) and drug  
36 targetable gene expression with expression quantitative trait loci in blood. Further, we  
37 investigated association between the SNPs and BC risk with genome-wide association study  
38 summary statistics. We then confirmed the hits from Mendelian randomization with tissue-  
39 specific analyses along with additional sensitivity assessments (horizontal pleiotropy,  
40 colocalization, multiple tissue enrichment etc.).

### 41 Results

42 The overall BC risk was decreased 16% with one standard deviation (SD) increase of  
43 *SLC12A2* gene expression in blood (odds ratio, 0.86, 95% confidential interval, 0.78-0.94).  
44 This signal was further confirmed in estrogen receptor positive (ER+) BC (0.85, 0.78-0.94).  
45 In addition, one SD increase in expression of *PDE1B* in blood was associated with 7%  
46 increased risk of ER+ BC (1.07, 1.03-1.11). We detected no evidence of horizontal pleiotropy  
47 for these associations and the probability of the causal variants being shared between the gene  
48 expression and BC risk was 81.5%, 40.5% and 66.8%, respectively. We failed to observe any  
49 significant association between other targeted genes and BC risk.

### 50 Conclusions

51 Use of antihypertensive medications that target *SLC12A2* and *PDE1B* is associated with  
52 increased and decreased BC risk, respectively.

### 53 Funding

54 This work was supported by the Swedish Research Council [2018-02400 to K.S., 2020-01175  
55 to J.S., 2021-01187 to J.J.], Cancerfonden [2017 CAN2017/340 to J.J.], Crafoordska  
56 Stiftelsen [to J.J.], MAS Cancer [to J.J.], ALF funding from Region Skåne [to J.J. and K.S.].  
57 The funding body was not involved in the design of the study and collection, analysis, and  
58 interpretation of data and in writing the manuscript.

## 59 INTRODUCTION

60 Nearly one in three adults is estimated to have hypertension globally (1). Antihypertensive  
61 drugs are the most commonly prescribed medication in Sweden with over 2.1 million patients  
62 taking anti-hypertensive drugs in 2020 (2). These drugs are usually prescribed to hypertensive  
63 patients as a long-term management (3). Given the large disease burden and high  
64 consumption of the antihypertensive medication, there are concerns surrounding their  
65 carcinogenic potential as well as interests regarding their possible anti-cancer effect since the  
66 targets of these drugs are widely distributed in normal tissue and may be involved in tumor  
67 development. For example, renin-angiotensin system, the target for angiotensin-converting  
68 enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), contains components  
69 that promote or inhibit cellular proliferation (4). Many observational studies with cohort or  
70 case-control design have evaluated the possible link between antihypertensive medication and  
71 risk of breast cancer (BC) (5-7), the most common type of cancer and the leading cause of  
72 cancer death among women worldwide (8). However, the results are conflicting, as these  
73 studies suffer from various biases, including unmeasured confounding, immortal time bias,  
74 indication and surveillance bias, which might result in inconsistent conclusions. Due to such  
75 shortcomings of the observational studies, previous results could not draw causative  
76 conclusions. In addition, there are ethical constraints for conducting randomized clinical trials  
77 (RCTs). Therefore, we opted for an alternative design to investigate the causal effect of anti-  
78 hypertensive medications on BC risk.

79 Mendelian randomization (MR) mimics a natural experiment by using genetic variants as a  
80 proxy (instrumental variable) for the modifiable exposure (9). The principle is that  
81 randomization occurs naturally at conception when genetic variants are allocated at random to  
82 individuals from their parents. Consequently, the inherited genetic variants are independent of  
83 potential confounding environmental exposures. MR can be regarded as analogous to an RCT  
84 that uses genetic variation as the method of randomization ultimately providing causal  
85 insights. In addition, the risk estimated from MR reflects a lifetime risk, which is longer than  
86 the follow-up in RCT. MR has successfully identified unintended drug effects including  
87 adverse drug effects and drug repurposing (10, 11). As for the association between  
88 antihypertensive medication and cancer risk, *Yarmolinsky et. al.* reported long-term ACE  
89 inhibition to be associated with an increased risk of colorectal cancer by using a MR analysis  
90 (12). However, the ARB, a common antihypertensive medication (13), was not included in the  
91 analysis. Additionally, the instrumental variable for each class of drug was selected based on

92 only one targeted gene. However, antihypertensive drugs may act on multiple targets involved  
93 in different pathways, thus capturing all the possible targets with corresponding instrumental  
94 variables for each drug are needed. Finally, the expression quantitative trait loci (eQTL) for  
95 the targeted genes from *Yarmolinsky et. al.* was derived only from the whole blood, whereas  
96 the targeted genes may be differentially expressed in a tissue-specific manner (14).

97 Here we aimed to investigate the effect of antihypertensive medication use on BC risk using a  
98 two-sample MR design with a consideration of all the commonly prescribed medication for  
99 hypertension, and exploring the eQTL from both the whole blood and several other tissues.  
100 This study will add evidence to the current knowledge derived from observational studies and  
101 try to draw causal conclusions regarding the potential association between antihypertensive  
102 medication use on BC risk.

103

## 104 MATERIAL AND METHODS

105 This study is based on a couple of publicly available databases, which are summarized in the  
106 **Supplementary Table 1**. We used the summary statistics of these publically available  
107 databases, and we did not access individual information. We constructed a two-sample MR  
108 design where the summary statistics for the association measures are independently evaluated  
109 for the exposure (i.e., genetic component and the gene expression) and the outcome (i.e.,  
110 genetic component and BC). We began by assessing the association between a single-  
111 nucleotide polymorphism (SNP) and drug targeted gene expression derived from publicly  
112 derived eQTL data in whole blood. In this, three basic assumptions must have held (9): 1) The  
113 genetic variants are associated with the risk factor of interest (relevance assumption); 2) There  
114 are no unmeasured confounders of the associations between genetic variants and outcome  
115 (independence assumption); 3) The genetic variants affect the outcome only through their  
116 effect on the risk factor of interest (exclusion restriction). To evaluate and establish the  
117 significant MR associations, we further performed tissue-specific analyses to confirm the hits  
118 along with additional sensitivity analyses, including assessment of horizontal pleiotropy,  
119 colocalization analysis, and multiple tissue enrichment evaluations. The design flow chart is  
120 demonstrated in **Figure 1**.

### 121 1. Identification of drug target genes

122 The commonly prescribed antihypertensive medications, including ACEis, ARBs, beta-  
123 blockers (BB), calcium channel blockers (CCB), diuretics and antihypertensives, were  
124 considered in the analysis (13). We identified the genes targeted by different classes of anti-  
125 hypertensive medication through DrugBank (15).

## 126 **2. Discovery of genetic instruments for targeted gene expression**

127 To identify common SNPs (minor allele frequency >1%) associated with the targeted gene  
128 expression of antihypertensive drug in blood, we extracted publicly available expression  
129 quantitative trait loci (eQTL) data from eQTLGen (<https://www.eqtlgen.org/>). The consortium  
130 incorporates 37 datasets, with a total of 31,684 individuals and reports on 16,987 genes  
131 expressed in whole blood. The eQTL SNPs for this analysis were from *cis*-regulated regions  
132 (2 Mb). We used F statistic to assess the strength of the instrumental SNPs.

## 133 **3. Validation of genetic instrument with systolic blood pressure GWAS**

134 Given that we are trying to identify instruments for blood pressure-lowering medication, we  
135 performed two-sample MR analysis with gene expression in blood (using the eQTL data) as  
136 exposure and systolic blood pressure (SBP) as the outcome to ensure we have valid  
137 instruments for the medication of interest. The summary statistics for SBP was a GWAS of  
138 SBP in 757 601 individuals of European ancestry drawn from UK Biobank (UKB) and the  
139 International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) (16).  
140 The summary-based MR (SMR) method (version 1.02) was used to perform the two-sample  
141 MR analysis (17). It tests a top SNP against the eQTL summary. For SNPs that passed the  
142 significance threshold for the SMR test (i.e.,  $P < 0.05$ ), additionally we performed the HEIDI  
143 (heterogeneity in dependent instruments) test to distinguish pleiotropy from linkage with  $P$ -  
144 value threshold of 0.01, in which up to the top 20 SNPs by default were used for  
145 heterogeneity test with LD pruning (0.05 -0.9) (17).

146

## 147 **4. Accumulation of genetic summary statistics for breast cancer risk**

148 We obtained publicly available GWAS summary statistics for BC risk from the Breast Cancer  
149 Association Consortium (BCAC). The analysis for the overall BC risk included 118,474 cases  
150 and 96,201 controls of European ancestry participating in 82 studies (18). For analyses of BC  
151 molecular subtypes, 7,325 participants were included for luminal A-like cases, 1,779 for  
152 luminal B/HER2-negative-like cases, 1,682 for luminal B-like cases, 718 for HER2-enriched-

153 like, 2,006 for triple-negative cases and 20,815 for controls (18). We also obtained the GWAS  
154 summary statistics for estrogen receptor-positive (ER+) and -negative (ER-) BC from BCAC,  
155 which contained 69,501 ER+ BC cases, 21,468 ER- BC cases and 105,974 controls (19).

## 156 **5. MR analysis between targeted gene expression in blood and breast cancer risk**

157 We performed MR analysis to estimate the association between target gene expression change  
158 (using whole blood eQTL) and BC risk (using GWAS). Bonferroni correction was used to  
159 identify significant associations due to multiple testing. For the association that reached  
160 corrected significant level, we generated SMR locus plot using the method presented on SMR  
161 webpage (<https://yanglab.westlake.edu.cn/software/smr/#Overview>).

## 162 **6. Sensitivity analyses**

163 **6.1 Colocalization analysis** This analysis is to assess if two independent association signals  
164 at the same locus, typically generated by two GWAS studies, are consistent with a shared  
165 causal variant. In the context of our study, we examined if the drug targeted gene expression  
166 and occurrence of BC in statistically significant MR associations shared a common causal  
167 variant by applying a Bayesian localization approach (20). As a convention, the posterior  
168 probability larger than 0.80 is considered supportive for a common causal variant. The R  
169 package ‘coloc’ (v3.1, <https://cran.r-project.org/web/packages/coloc/>) was used to perform  
170 the test.

171 **6.2 Assessment of horizontal pleiotropy** A genetic variant can be associated with more than  
172 one gene expression, which is known as horizontal pleiotropy. Horizontal pleiotropy is a  
173 violation of the instrumental variable assumption (exclusion restriction) that the genetic  
174 instrument is associated with the outcome only via changes in gene expression of the drug  
175 target. We tested for horizontal pleiotropy by extracting available associations with all other  
176 nearby genes (within a 2Mb window) for each genetic instrument. For the nearby genes  
177 showing significant association with the genetic instrument, we performed SMR analysis to  
178 test if the expression of these genes was associated with BC risk. For those genes with  
179 significant SMR associations, colocalization analysis was performed to estimate the  
180 probability that two association signals share the same causal variant.

181 **6.3 Multiple tissue sensitivity** We then evaluated the impact of the actionable targets in  
182 several different tissues along with whole blood and breast epithelium. Gene set enrichment  
183 analysis was performed with the assorted drug target genes to quantify all biological pathways

184 prone to be affected by the drugs. RNA seq data on different tissues (except prostate and  
185 testis) were utilized for this purpose and analyzed with R package ‘TissueEnrich’ (21). The  
186 enrichment analysis queries expression modulation with fold changes across different human  
187 tissue types. A significant departure was defined at an adjusted fold change in expression of  
188 value 2 and the fold change was also tested for statistical significance. For tissues that showed  
189 significant fold changes, further MR association between tissue specific eQTL and BC risk  
190 were retrieved from summary statistics reported by Barbeira et. al. (22).

191 **6.4 Differential gene expression in Expression Atlas** To verify the associations that have  
192 shown causal variant and signaled no horizontal pleiotropy, we retrieved transcriptomic data  
193 of the significant genes for tumor tissue (or other tissue from BC patients) and normal tissue  
194 (or other tissue from healthy controls) on Expression Atlas (<https://www.ebi.ac.uk/gxa/home>).  
195 Differential gene expressions between tissues were evaluated as fold change using normal  
196 tissue (or other tissue from healthy controls) as reference.

#### 197 **6.5 MR analysis to estimate the association of SBP with breast cancer**

198 To determine whether the association between drug targeted gene expression and BC risk is  
199 likely to be mediated via changes in blood pressure or whether the association may be driven  
200 independently, we estimated the effect size for the association between genetically estimated  
201 SBP and BC using the generalized summary data-based MR (GSMR) method (23). The  
202 GSMR (implemented in Genome-wide Complex Trait Analysis, version 1.91.7) is an  
203 extension of SMR that uses multiple genetic variants associated with the risk factor to test for  
204 potential causality. The above-mentioned GWAS summary statistics on SBP (exposure) and  
205 overall BC risk (outcome) in European individuals were used for the analysis. As usual, a  
206 HEIDI  $P < 0.01$  was used to detect outlying variants. In addition, we performed two-sample  
207 MR analysis using “*Two-Sample MR*” R package to check the consistency of the signals from  
208 the two different methods.

209

## 210 **RESULTS**

### 211 **Genetic Instrument Selection and Validation**

212 We identified a total of 164 blood pressure modulatory drugs from the WHO Collaborating  
213 Centre for Drug Statistics Methodology (<https://www.whocc.no/>). In DrugBank database, 124  
214 of them were identified to target a total of 154 genes. There were expectedly several overlaps



215 between drug classes and associated targets (**Figure 2**, details in **Supplementary Table 2**).  
216 For example, *SLC12A2* can be targeted by quinethazone, bumetanide and torasemide, and at  
217 the same time, torasemide can also target on gene *SLC12A1*. Among the 154 chosen targeted  
218 genes, 72 genes were identified to have strong association with the eQTL SNPs in eQTLGen  
219 (F statistic > 10,  $P_{\text{eQTL}} < 1\text{e-}8$ ), among which, 32 were found to be causally associated with  
220 SBP with statistical significance ( $P < 0.05$ ). A total of 23 associations were confirmed by the  
221 HEIDI outlier test ( $p_{\text{HEIDI}} > 0.01$ ), which were further considered in the MR analysis with  
222 BC as the outcome (**Supplementary Table 3**). It should be noted that the number of SNPs in  
223 HEIDI test for gene *P4HA1* was less than five ( $n=3$ ).

#### 224 **MR analysis for association of targeted gene in blood and overall and subtypes BC risk**

225 In the analysis of MR association between the targeted genes in blood and overall BC risk, we  
226 identified significant associations for five genes including *P4HA1*, *SLC12A2*, *KCNJ11*, *CA12*  
227 and *PDE1B*, but only the association for *SLC12A2* was significant with Bonferroni correction  
228 ( $0.05/23=2.2 \times 10^{-3}$ ) (**Table 1**). One standard deviation increase in the expression of *SLC12A2*  
229 was associated with 14% decrease in BC risk (odds ratio, OR, 0.86, 95% confidence interval,  
230 95%CI, 0.78-0.94). This association was supported by the HEIDI outlier test. The SMR locus  
231 plot for this association is shown in **Figure 3**. With the same analysis for ER+ and ER- BC  
232 (**Table 2**), a nominal significance was observed in the association between ER+ BC risk and  
233 expressions of *P4HA1*, *SLC12A2*, *KCNJ11* and *PDE1B*, among which *SLC12A2* and *PDE1B*  
234 were still significant after Bonferroni correction ( $0.05/(23 \times 2)=1.1 \times 10^{-3}$ ). One SD increase in  
235 the *SLC12A2* expression was associated with 15% decrease in the risk of ER+ BC (0.85, 0.78-  
236 0.94), while one SD increase in *PDE1B* expression was associated with 7% increased risk  
237 (1.07, 1.03-1.11). For ER- BC, only *SLC12A2* showed a nominal significance but it was not  
238 significant while considering multiple testing. For the molecular subtype of BC (see **Table 2**),  
239 we found *P4HA1*, *SLC12A2*, *KCNJ11* and *CA12* were associated with luminal A-like BC with  
240 nominal significance, *P4HA1*, *SLC12A2*, *ATP1A1*, *NR3C1*, *CA12*, *CACNA1D* and *GPR35* for  
241 luminal B-like BC, *SLC12A2* and *SCNN1D* for luminal B/HER2-negative-like BC, ACE for  
242 HER2-enriched-like BC and AOC1 for triple-negative BC. However, none of them was  
243 significant after Bonferroni correction ( $0.05/(23 \times 5)=4.3 \times 10^{-4}$ ).

#### 244 **Sensitivity analyses**

245 We conducted several sensitivity analyses to evaluate the discovered significant associations  
246 between targetable gene expression and BC risk. The associations for the top SNP pertaining



247 to *SLC12A2* and *PDE1B* with nearby genes within the 2MB window are shown in  
248 **Supplementary Table 4**. In the test for horizontal pleiotropy, gene *CTC-228N24.3* within the  
249 2MB window of *SLC12A2* was also found significant association with BC risk  
250 (**Supplementary Table 5**). The P-value of the SMR association for *CTC-228N24.3* was  
251 similar to that of *SLC12A2*. However, the posterior probability for a common variant between  
252 *CTC-228N24.3* and overall BC risk was 77%, less than that for *SLC12A2* (81.5%). The  
253 posterior probability for a common causal variant between *SLC12A2* expression and risk of  
254 ER+ BC was 40.5% and for *PDE1B* was 66.8%. None of the corresponding nearby genes  
255 showed a higher probability than *SLC12A2* and *PDE1B*.

256 In the tissue enrichment analysis, 16 different tissues were found enriched with targeted genes  
257 (**Supplementary Figure 1**). We further measured the statistical significance of the  
258 associations which largely overlapped with the observation of fold change. Interestingly,  
259 smooth muscular, cervical, gallbladder, endometrium, adrenal gland, small seven intestine,  
260 placenta, skeletal muscle and kidney were found significant. The MR associations for the  
261 available tissue in GTEx are shown in **Supplementary Table 6**. Only expression of *PDE1B*  
262 in mammary tissue was negatively associated with BC risk (OR, 0.88, 95%CI, 0.82-0.95), but  
263 it was not significant after considering Bonferroni correction ( $0.05/(23 \times 7) = 3.1 \times 10^{-4}$ ).

264 We uncovered five data resources in Expression Atlas (see **Supplementary Table 7**), which  
265 contained gene expression of *SLC12A2* for invasive BC tissue (or other tissue from BC  
266 patients) and normal tissue (or other tissue from healthy controls). The samples were either  
267 from blood or breast tissue. Four datasets indicated that *SLC12A2* expression in BC tissue (or  
268 blood from BC patients) was lower than that in normal tissue (or blood from healthy  
269 controls). Only one showed the opposite association and the type of the BC was invasive  
270 ductal carcinoma.

#### 271 **MR association between systolic blood pressure and overall BC risk**

272 We performed MR with GSMR and TwoSampleMR to test if SBP was associated with  
273 overall BC risk using SBP GWAS data as exposure and BC GWAS as the outcome. The  
274 results indicated no evidence of the causal association between genetically estimated SBP and  
275 BC risk (**Supplementary Table 8**).

276

#### 277 **DISCUSSIONS**

278 With this two-sample Mendelian randomization study, we observed that the overall BC risk  
279 was decreased 16% along with one SD increase of *SLC12A2* gene expression. *SLC12A2*  
280 encodes Na(+)-K(+)-2Cl(-) cotransporter isoform 1 (NKCC1), which can be targeted by loop  
281 diuretics including torasemide, bumetanide and quinethazone. Thus, long-term use of these  
282 drugs may potentially increase overall BC risk. The significant association with the  
283 expression of *SLC12A2* was further observed with ER+ BC. In addition, a SD increase in  
284 expression of *PDE1B*, which can be targeted by three CCBs: nifedipine, felodipine and  
285 bepridil, was associated with 7% increased risk of ER+ BC. We did not observe any  
286 significant association between other targeted genes and BC risk.

287 A recent meta-analysis evaluated the association between antihypertensive medication use  
288 and BC according to 57 conventional observational studies and also reported that use of  
289 diuretics was associated with increased BC risk (24). However, this study also found  
290 increased BC risk among users of BBs, or CCBs (24), which is inconsistent with our result.  
291 Another meta-analysis based on RCTs concluded no consistent evidence that antihypertensive  
292 medication use had any effect on cancer risk (25). Our results are in agreement with the  
293 findings from *Yarmolinsky et. al.* who investigated antihypertensive drug use and risk of  
294 common cancers by evaluating SNPs in *ACE*, *ADRB1*, and *SLC12A3* in GWAS of SBP to  
295 proxy genetic inhibition of the angiotensin-converting enzyme (*ACE*),  $\beta$ -1 adrenergic receptor  
296 (*ADRB1*), and sodium-chloride symporter (*NCC*) (12). None of the inhibited targets were  
297 associated with the risk of BC (12). Unlike this MR study which only considered one targeted  
298 gene for each type of antihypertensive drug, we included all the targets and validated the  
299 instruments through systolic blood pressure GWAS.

300 The mechanisms that links *SLC12A2* gene expression and BC risk are unclear. The GSMR  
301 analysis for the association between SBP and BC risk indicates that the effect of the drugs on  
302 BC risk was not through blood pressure, which is consistent with the finding that there is no  
303 evidence of genetic correlation between blood pressure and BC risk (26). The *SLC12A2*-  
304 coded protein, NKCC1 has been reported to be involved in mammary gland development and  
305 regulate breast morphogenesis (27). So far, very few studies have investigated the association  
306 of BC risk and use of loop diuretics, although among which furosemide targets also NKCC2,  
307 a homogeneous protein of NKCC1. A meta-analysis based on four studies found that the  
308 relative risk of BC among users of loop diuretics was 0.91(0.77-1.06) compared to nonusers.  
309 Elsewhere an in vitro study reported expression of *SLC12A2* in BC cell to be downregulated  
310 by the treatment with estrogen (28), which is a well-known risk factor for BC. This finding is

311 in accordance with our current study where *SLC12A2* expression was found protective against  
312 BC risk and this association was only significant for ER+ BC. It should be noted that the case  
313 number of ER-BC GWAS was much less than ER+ BC GWAS which might detail the loss of  
314 signal. Four out of five datasets from Expression Atlas also indicated lower expression of  
315 *SLC12A2* in BC tissue (or tissue from BC patients) than the normal tissue (or tissue from  
316 controls). On contrary, several in vitro studies reported that inhibition of NKCC1 could  
317 reduce cell proliferation, invasion and/or migration in glioblastoma, glioma, esophageal  
318 squamous cell carcinoma, hepatocellular carcinoma and gastric cancer cells which may  
319 indicate a global underlying tumor-inhibiting mechanism (29-35). Sun et. al. also found that  
320 increased expression of NKCC1 was associated with poor prognosis in lung adenocarcinoma  
321 and EGFR-mutated adenocarcinoma (36). More studies are required to investigate the role of  
322 NKCC1 in BC etiology.

323 *PDE1B* was the only other gene that showed the association with ER+BC risk. The function  
324 of protein PDE1B includes dopaminergic signaling, immune cell activation, and cell survival.  
325 It is one of the family members of phosphodiesterases (PDEs) that hydrolyze cyclic adenosine  
326 monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP); the latter two  
327 participate in many physiological processes such as visual transduction, cell proliferation and  
328 differentiation, and cell-cycle regulation (37). Some tumor cells overexpress PDEs and as a  
329 consequence, the level of cAMP/cGMP in tumor cells is lower than the normal cells (38).  
330 PDEs have become the potential therapeutic target to increase intracellular cAMP/cGMP and  
331 thus inhibit tumor growth (39, 40). PDE1B can be targeted by miR-5701 to inhibit  
332 proliferation and promote apoptosis of clear cell renal cell carcinoma cells (41). Wittliff et.al.  
333 used gene expression of *PDE1B* and several other genes to predict the overall survival of  
334 breast carcinoma (42). However, in the tissue-specific MR, the results for the mammary gland  
335 contradict the current evidence, which needs further investigation.

336 We need to emphasize the strengths and weaknesses of the causal nature of this study design.  
337 Use of GWAS summary statistics with two sample MR increases statistical power. The  
338 application of genetic variants to proxy the use of antihypertensive medication reduces the  
339 chance of confounding, misclassification and immortal time bias that are common caveats in a  
340 conventional observational study (43). The different targeted-gene expression was obtained  
341 since fetus, which provides the opportunity to observe the effect of antihypertensive  
342 medication on BC risk in a long term. Compared to RCT, our study is more efficient as cancer  
343 is a late-onset disorder and needs long-term follow-up time. Using the plethora of publicly

344 available summary statistics from GWAS, MR was performed without recruiting new patients  
345 or designing additional studies like RCT. We conducted multiple sensitivity analyses such as  
346 colocalization analysis and pleiotropy test to evaluate the viability of the assumptions of the  
347 instrument variables and to reduce chance findings. As for limitations, the exploration of the  
348 molecular subtype of BC was underpowered due to small sample size. Larger GWAS data  
349 from the consortium are needed to remedy such issue. The effect of differed gene expression  
350 on BC risk due to polymorphism may not be the same as that due to the use of  
351 antihypertensive medication, as the former exposure is from early-life time and the latter  
352 mostly from adulthood. Therefore, our results provide a strong signal to select existing drugs  
353 (NKCC1-targeted antihypertensive medication) to be validated with RCT. Our results may  
354 only be applied to European population and research among other population is needed.  
355 Additionally, our results suggest future studies could focus on the association between  
356 expression level of NKCC1 protein and BC risk, which may provide evidence on risk  
357 reduction.

358

## 359 CONCLUSIONS

360 By using two-sample MR, we found BC risk was negatively associated with expression of  
361 *SLC12A2*, and ER+ BC risk was positively associated with expression of *PDE1B*. Therefore,  
362 the use of antihypertensive medication targeting *SLC12A2* and *PDE1B* will be associated  
363 respectively increased and decreased risk. The observed effect on the BC risk was  
364 independent of systolic blood pressure.

365

## 366 DECLARATIONS

367 **Availability of data and materials:** The data that support the findings of this study are  
368 publicly available. The sources have been summarized in **Supplementary Table 1**. Any  
369 request regarding the data from this study should go to Z.G..

370 **Ethical approval and consent to participate:** All the data for this study were publicly  
371 available summary statistics. Therefore, ethical approval and consent to participate were not  
372 required.

373 **Consent for publication:** Not applicable.

374 **Competing interests:** The authors declare no competing interests.

375 **Author contributions:** Design: GZ, JJ. Work platform access: JS, KS. Statistical analysis and  
376 interpretation: GZ, SC, JJ, JS, KS. Manuscript writing: GZ and all other authors. Approval of  
377 the final text: All authors.

378

379 **REFERENCE:**

- 380 1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nature Reviews*  
381 *Nephrology*. 2020;1-15.
- 382 2. Statistik om läkemedel 2020. 2021.
- 383 3. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast  
384 cancer. *Nature Reviews Disease Primers*. 2019;5(1):66.
- 385 4. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. The renin-  
386 angiotensin system meets the hallmarks of cancer. *Journal of the Renin-Angiotensin-Aldosterone*  
387 *System*. 2015;16(2):227-33.
- 388 5. Li CI, Daling JR, Tang M-TC, Haugen KL, Porter PL, Malone KE. Use of antihypertensive  
389 medications and breast cancer risk among women aged 55 to 74 years. *JAMA internal medicine*.  
390 2013;173(17):1629-37.
- 391 6. Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, et  
392 al. The use of antihypertensive medication and the risk of breast cancer in a case-control study in a  
393 Spanish population: the MCC-Spain study. *PLoS One*. 2016;11(8):e0159672.
- 394 7. Raebel MA, Zeng C, Cheetham TC, Smith DH, Feigelson HS, Carroll NM, et al. Risk of  
395 Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme  
396 Inhibitors Among Older Women. *American Journal of Epidemiology*. 2017;185(4):264-73.
- 397 8. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics  
398 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  
399 *CA: a cancer journal for clinicians*. 2018;68(6):394-424.
- 400 9. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a  
401 guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.
- 402 10. Yin P, Anttila V, Siewert KM, Palotie A, Davey Smith G, Voight BF. Serum calcium and  
403 risk of migraine: a Mendelian randomization study. *Hum Mol Genet*. 2017;26(4):820-8.
- 404 11. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al.  
405 HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic  
406 analysis and randomised trials. *Lancet*. 2015;385(9965):351-61.
- 407 12. Yarmolinsky J, Diez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Pare G, et al.  
408 Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common  
409 cancers. *medRxiv*. 2021.
- 410 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018  
411 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the  
412 management of arterial hypertension of the European Society of Cardiology (ESC) and the European  
413 Society of Hypertension (ESH). *European heart journal*. 2018;39(33):3021-104.

- 414 14. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, et al.  
415 Genome-wide association and transcriptome studies identify target genes and risk loci for breast  
416 cancer. *Nature communications*. 2019;10(1):1-18.
- 417 15. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major  
418 update to the DrugBank database for 2018. *Nucleic acids research*. 2018;46(D1):D1074-D82.
- 419 16. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic  
420 analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat*  
421 *Genet*. 2018;50(10):1412-25.
- 422 17. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary  
423 data from GWAS and eQTL studies predicts complex trait gene targets. *Nature genetics*.  
424 2016;48(5):481-7.
- 425 18. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide  
426 association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-  
427 specific analyses. *Nature Genetics*. 2020;52(6):572-81.
- 428 19. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, et al.  
429 Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat*  
430 *Genet*. 2017;49(12):1767-78.
- 431 20. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.  
432 Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.  
433 *PLoS Genet*. 2014;10(5):e1004383.
- 434 21. Jain A, Tuteja G. TissueEnrich: Tissue-specific gene enrichment analysis.  
435 *Bioinformatics*. 2018;35(11):1966-7.
- 436 22. Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, et al.  
437 Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. *Genome Biology*.  
438 2021;22(1):49.
- 439 23. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations  
440 between risk factors and common diseases inferred from GWAS summary data. *Nature*  
441 *communications*. 2018;9(1):1-12.
- 442 24. Xie Y, Wang M, Xu P, Deng Y, Zheng Y, Yang S, et al. Association Between  
443 Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis.  
444 *Frontiers in pharmacology*. 2021;12:1169.
- 445 25. Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, et al.  
446 Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. *The*  
447 *Lancet Oncology*. 2021;22(4):558-70.
- 448 26. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, et al. Shared  
449 heritability and functional enrichment across six solid cancers. *Nature Communications*.  
450 2019;10(1):431.
- 451 27. Shillingford JM, Miyoshi K, Flagella M, Shull GE, Hennighausen L. Mouse mammary  
452 epithelial cells express the Na-K-Cl cotransporter, NKCC1: characterization, localization, and  
453 involvement in ductal development and morphogenesis. *Molecular endocrinology*. 2002;16(6):1309-  
454 21.
- 455 28. Wright PK, May FE, Darby S, Saif R, Lennard TW, Westley BR. Estrogen regulates vesicle  
456 trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. *International journal of*  
457 *clinical and experimental pathology*. 2009;2(5):463.
- 458 29. Luo L, Guan X, Begum G, Ding D, Gayden J, Hasan MN, et al. Blockade of cell volume  
459 regulatory protein NKCC1 increases TMZ-induced glioma apoptosis and reduces astrogliosis.  
460 *Molecular cancer therapeutics*. 2020;19(7):1550-61.
- 461 30. Zhou Y, Sun W, Chen N, Xu C, Wang X, Dong K, et al. Discovery of NKCC1 as a potential  
462 therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis. *Oncotarget*.  
463 2017;8(39):66328.



- 464 31. Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang S-S, et al. Inhibition of Na<sup>+</sup>-  
465 K<sup>+</sup>-2Cl<sup>-</sup>-cotransporter isoform 1 accelerates temozolomidemediated apoptosis in glioblastoma cancer  
466 cells. *Cellular Physiology and Biochemistry*. 2012;30(1):33-48.
- 467 32. Haas BR, Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter  
468 isoform-1 reduces glioma invasion. *Cancer research*. 2010;70(13):5597-606.
- 469 33. Wang J-f, Zhao K, Chen Y-y, Qiu Y, Zhu J-h, Li B-p, et al. NKCC1 promotes proliferation,  
470 invasion and migration in human gastric cancer cells via activation of the MAPK-JNK/EMT signaling  
471 pathway. *Journal of Cancer*. 2021;12(1):253.
- 472 34. Schiapparelli P, Guerrero-Cazares H, Magaña-Maldonado R, Hamilla SM, Ganaha S,  
473 Fernandes EGL, et al. NKCC1 regulates migration ability of glioblastoma cells by modulation of actin  
474 dynamics and interacting with cofilin. *EBioMedicine*. 2017;21:94-103.
- 475 35. Shiozaki A, Nako Y, Ichikawa D, Konishi H, Komatsu S, Kubota T, et al. Role of the  
476 Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup>-cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell  
477 carcinoma. *World Journal of Gastroenterology: WJG*. 2014;20(22):6844.
- 478 36. Sun P-L, Jin Y, Park SY, Kim H, Park E, Jheon S, et al. Expression of Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>-  
479 cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated  
480 adenocarcinoma patients. *QJM: An International Journal of Medicine*. 2016;109(4):237-44.
- 481 37. Peng T, Gong J, Jin Y, Zhou Y, Tong R, Wei X, et al. Inhibitors of phosphodiesterase as  
482 cancer therapeutics. *European journal of medicinal chemistry*. 2018;150:742-56.
- 483 38. Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase  
484 function and endocrine cells: links to human disease and roles in tumor development and treatment.  
485 *Current opinion in pharmacology*. 2011;11(6):689-97.
- 486 39. Huang W, Sundquist J, Sundquist K, Ji J. Phosphodiesterase-5 inhibitors use and risk for  
487 mortality and metastases among male patients with colorectal cancer. *Nat Commun*.  
488 2020;11(1):3191.
- 489 40. Huang W, Sundquist J, Sundquist K, Ji J. Use of Phosphodiesterase 5 Inhibitors Is  
490 Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.  
491 *Gastroenterology*. 2019;157(3):672-81 e4.
- 492 41. Zhao C, Mo L, Lei T, Yan Y, Han S, Miao J, et al. miR-5701 promoted apoptosis of clear  
493 cell renal cell carcinoma cells by targeting phosphodiesterase-1B. *Anti-Cancer Drugs*. 2021;32(8):855-  
494 63.
- 495 42. Wittliff JL, Sereff SB, Daniels MW. Expression of genes for methylxanthine pathway-  
496 associated enzymes accompanied by sex steroid receptor status impacts breast carcinoma  
497 progression. *Hormones and Cancer*. 2017;8(5):298-313.
- 498 43. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel  
499 approach for the prediction of adverse drug events and drug repurposing opportunities. *International*  
500 *journal of epidemiology*. 2017;46(6):2078-89.

501

502

503

504

505

506

507

508

509



510

511

512

### 513 **FIGURE LEGENDS**

514 **Figure 1.** The flowchart of the study.

515 Mendelian randomization, SMR, summary-based MR, eQTL, expression quantitative trait  
516 loci, SNP, single-nucleotide polymorphism, HEIDI, heterogeneity in dependent instruments,  
517 BC, breast cancer.

518 **Figure 2.** A network of established links between hypertension drugs considered and the  
519 corresponding target genes.

520 Each color represents a different class of drugs (annotated in the histogram) and the circle size  
521 represents the number of drugs belonging to a class. Abbreviations: CCB, calcium channel  
522 blockers, BB, beta-blockers, AH, antihypertensives, ACEi, angiotensin-converting enzyme  
523 inhibitors, ARBs, angiotensin receptor blockers.

524 **Figure 3.** MR association between *SLC12A2* gene expression in blood and breast cancer risk

525 (a) Top, P values from the GWAS for breast cancer (grey dots) and P values from SMR tests  
526 (diamonds). Bottom, P values eQTL data for *SLC12A2* and *CTC-228N24.3*. Shown in a are all  
527 the SNPs available in the GWAS and eQTL data. (b) Effect sizes of the SNPs (used for the  
528 HEIDI test) from the GWAS against those from the eQTL data. The orange dashed lines  
529 represent the estimate of effect size of the MR association at the top cis-eQTL (rather than the  
530 regression line). Error bars are the standard errors of SNP effects.

531

532

**Table 1** MR association between drug target gene expression in blood and overall risk of breast cancer

Gene	ProbeChr	Probe_bp	topSNP	topSNP_chr	topSNP_bp	Effect_allele	Other_allele	Freq_Effect_allele	eQTL association			BC association			MR association			HEIDI Test	
									beta	se	p	beta	se	p	beta	se	p	p	nsnp
SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.2E-86	0.028	0.007	7.57E-05	-0.150	0.039	1.05E-04	1.56E-01	20
P4HA1	10	74811853	rs6480668	10	74849326	G	A	0.24	0.183	0.016	3.35E-32	-0.032	0.012	7.83E-03	-0.176	0.068	9.47E-03	4.98E-01	8
CA12	15	63643968	rs12909041	15	63743677	A	C	0.36	0.039	0.010	1.14E-04	-0.026	0.008	6.88E-04	-0.670	0.263	1.08E-02	5.35E-01	5
PDE1B	12	54958078	rs10747699	12	54955324	T	C	0.39	0.406	0.009	0.00E+00	0.017	0.007	1.31E-02	0.041	0.017	1.32E-02	3.63E-01	3
KCNJ11	11	17409142	rs2074310	11	17421886	T	C	0.26	0.157	0.012	4.37E-38	-0.015	0.006	1.99E-02	-0.092	0.040	2.20E-02	8.06E-02	20
NR3C1	5	142736286	rs4912908	5	142791133	G	A	0.17	0.073	0.010	1.07E-13	0.016	0.008	4.67E-02	0.221	0.115	5.47E-02	2.81E-02	15
ATP1A1	1	116934086	rs6704439	1	116867616	A	C	0.30	0.041	0.009	4.39E-06	0.015	0.008	5.47E-02	0.363	0.205	7.64E-02	8.28E-01	20
KCNJ2	17	68170501	rs9890133	17	68169005	G	A	0.15	-0.256	0.012	8.02E-94	-0.015	0.010	1.12E-01	0.060	0.038	1.13E-01	9.60E-01	20
SLC12A1	15	48540068	rs964611	15	48597514	A	C	0.15	1.664	0.009	0.00E+00	-0.012	0.009	1.78E-01	-0.007	0.005	1.78E-01	9.86E-01	20
CACNA2D2	3	50470954	rs62260815	3	50474624	A	G	0.05	-0.142	0.013	8.98E-29	-0.013	0.010	2.03E-01	0.089	0.070	2.06E-01	3.88E-01	20
AHR	7	17362011	rs17643734	7	17162882	G	A	0.03	0.478	0.016	3.7E-184	0.015	0.013	2.70E-01	0.030	0.028	2.71E-01	9.83E-01	20
ACE	17	61576813	rs4277405	17	61548918	C	T	0.35	0.075	0.009	1.59E-17	0.006	0.006	3.18E-01	0.083	0.084	3.21E-01	9.97E-01	20
AQP1	7	30929070	rs2075574	7	30950744	T	C	0.37	0.113	0.013	3.77E-19	-0.008	0.009	3.50E-01	-0.073	0.078	3.53E-01	7.67E-01	5
SLC9A1	1	27459389	rs6683016	1	27493194	T	C	0.28	-0.096	0.008	9E-31	-0.004	0.006	5.37E-01	0.041	0.066	5.38E-01	7.61E-02	20
AOC1	7	150540153	rs7806458	7	150476888	G	A	0.28	0.669	0.008	0.00E+00	-0.003	0.006	6.20E-01	-0.005	0.009	6.20E-01	7.63E-01	20
CACNA1H	16	1237506	rs117177120	16	1238875	G	T	0.02	0.372	0.024	4.41E-54	0.004	0.016	7.82E-01	0.012	0.042	7.82E-01	4.21E-01	20
SLC16A1	1	113477052	rs1049434	1	113456546	A	T	0.32	0.125	0.008	9.29E-54	0.002	0.006	8.02E-01	0.013	0.050	8.02E-01	4.06E-01	20
GPR35	2	241557762	rs2975788	2	241571858	G	A	0.43	0.293	0.009	6.2E-259	0.002	0.007	8.10E-01	0.005	0.022	8.10E-01	5.79E-01	20
CACNA1D	3	53687586	rs9830632	3	53735766	G	A	0.29	-0.085	0.009	2E-22	-0.001	0.007	9.19E-01	0.008	0.080	9.19E-01	3.50E-01	20
ADRB2	5	148207176	rs2082395	5	148200600	A	G	0.35	0.126	0.008	6.31E-56	-0.001	0.006	9.37E-01	-0.004	0.050	9.37E-01	7.18E-01	4
CA4	17	58237778	rs34820870	17	58244021	G	T	0.16	-0.462	0.021	6.1E-110	0.001	0.016	9.50E-01	-0.002	0.036	9.50E-01	9.89E-01	20
JUN	1	59248125	rs2716140	1	59472397	C	A	0.39	-0.228	0.008	3.5E-177	0.000	0.007	9.57E-01	0.002	0.030	9.57E-01	9.06E-01	20
SCNN1D	1	1221612	rs6662635	1	1220425	G	A	0.08	-0.475	0.044	4.76E-27	-0.001	0.031	9.80E-01	0.002	0.064	9.80E-01	9.46E-01	20

534 Beta of MR association represents the log odds per one standard deviation increase in gene expression. A significant HEIDI p-value (<0.01) indicates that any association  
535 between gene expression and outcome may be due to linkage where there are two distinct causal variants in linkage disequilibrium.

536 MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, BC, breast cancer, HEIDI, heterogeneity in  
537 dependent instruments, nsnp, number of SNPs for HEIDI test.

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557 **Table 2** MR association between drug target gene expression in blood and risk of breast cancer subtype according to ER status and molecular characteristics

BC type		Gene	Pr ob eChr	Probe_bp	topSNP	topSNP_chr	topSNP_bp	Effect _allele	Othe r_allele	Fre q_Effect _allele	eQTL association			BC association			MR association			HEIDI Test	
											beta	se	p	beta	se	p	beta	se	p	p	ns np
Estrogen receptor status	Positive	P4HA1	10	74811853	rs6480668	10	74849326	G	A	0.24	0.183	0.016	3.35E-32	-0.045	0.015	2.49E-03	-0.247	0.084	3.30E-03	3.72E-01	8
		SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.029	0.009	6.96E-04	-0.158	0.048	8.67E-04	1.23E-01	20
		KCNJ11	11	17409142	rs2074310	11	17421886	T	C	0.26	0.157	0.012	4.37E-38	-0.016	0.008	4.20E-02	-0.099	0.050	4.53E-02	4.33E-01	20
		PDE1B	12	54958078	rs1874308	12	54954356	A	T	0.39	0.429	0.009	0.00E+00	0.030	0.008	3.38E-04	0.070	0.019	3.28E-04	2.37E-01	14
	Negative	SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.037	0.013	5.13E-03	-0.200	0.072	5.75E-03	7.17E-01	20
molecular characteristics	Luminal A-like	P4HA1	10	74811853	rs6480668	10	74849326	G	A	0.24	0.183	0.016	3.35E-32	-0.044	0.016	6.35E-03	-0.238	0.090	7.84E-03	9.37E-01	8
		PDE1B	12	54958078	rs1874308	12	54954356	A	T	0.39	0.429	0.009	0.00E+00	0.023	0.009	9.75E-03	0.053	0.020	9.86E-03	5.67E-01	14
		CA12	15	63643968	rs12909041	15	63743677	A	C	0.36	0.039	0.010	1.14E-04	-0.024	0.010	1.51E-02	-0.632	0.307	3.97E-02	5.06E-01	6
		SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.019	0.009	4.35E-02	-0.101	0.050	4.46E-02	9.57E-01	20
	Luminal B-like	P4HA1	10	74811853	rs6480668	10	74849326	G	A	0.24	0.183	0.016	3.35E-32	-0.093	0.037	1.11E-02	-0.506	0.204	1.31E-02	9.98E-01	8
		GPR35	2	241557762	rs2975788	2	241571858	G	A	0.43	0.293	0.009	6.23E-259	-0.044	0.019	2.02E-02	-0.151	0.065	2.05E-02	1.21E-02	20
		SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.044	0.020	3.24E-02	-0.236	0.111	3.34E-02	1.73E-02	20
		CACNA1D	3	53687586	rs9830632	3	53735766	G	A	0.29	-0.085	0.009	2.00E-22	0.042	0.020	3.17E-02	-0.499	0.238	3.59E-02	6.17E-01	20
		CA12	15	63643968	rs12909041	15	63743677	A	C	0.36	0.039	0.010	1.14E-04	-0.056	0.023	1.29E-02	-1.457	0.697	3.66E-02	8.70E-01	6
		ATPIA1	1	116934086	rs6704439	1	116867616	A	C	0.30	0.041	0.009	4.39E-06	0.050	0.022	2.10E-02	1.216	0.590	3.92E-02	9.63E-01	20
		NR3C1	5	142736286	rs4912908	5	142791133	G	A	0.17	0.073	0.010	1.07E-13	0.047	0.023	3.76E-02	0.649	0.324	4.53E-02	3.31E-01	14
	luminal B/HER2-negative-like	SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.054	0.017	1.82E-03	-0.292	0.095	2.08E-03	6.53E-01	20
		SCNN1D	1	1221612	rs6662635	1	1220425	G	A	0.08	-0.475	0.044	4.76E-27	-0.206	0.080	1.03E-02	0.434	0.174	1.26E-02	3.35E-01	20
	HER2-enriched	KCNJ11	11	17409142	rs2074310	11	17421886	T	C	0.26	0.157	0.012	4.37E-38	-0.041	0.027	1.28E-01	-0.258	0.171	1.31E-01	6.21E-01	20
		ACE	17	61576813	rs4277405	17	61548918	C	T	0.35	0.075	0.009	1.59E-17	0.069	0.026	7.99E-03	0.918	0.363	1.13E-02	1.93E-01	20
Triple-negative	AOC1	7	150540153	rs7806458	7	150476888	G	A	0.28	0.669	0.008	0.00E+00	-0.031	0.016	4.97E-02	-0.046	0.024	4.97E-02	9.62E-01	20	

559 Beta of MR association represents the log odds per one standard deviation increase in gene expression. A significant HEIDI p-value ( $<0.01$ ) indicates that any association  
560 between gene expression and outcome may be due to linkage where there are two distinct causal variants in linkage disequilibrium.

561 MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, BC, breast cancer, HEIDI, heterogeneity in  
562 dependent instruments, nsnp, number of SNPs for HEIDI test.




Figure 1. The flowchart of the study. Mendelian randomization, SMR, summary-based MR, eQTL, expression quantitative trait loci, SNP, single-nucleotide polymorphism, HEIDI, heterogeneity in dependent instruments, BC, breast cancer.




Figure 2. A network of established links between hypertension drugs considered and the corresponding target genes. Each color represents a different class of drugs (annotated in the histogram) and the circle size represents the number of drugs belonging to a class. Abbreviations: CCB, calcium channel blockers, BB, beta-blockers, AH, antihypertensives, ACEi, angiotensin-converting enzyme inhibitors, ARBs, angiotensin receptor blockers.







Figure 3. MR association between SLC12A2 gene expression in blood and breast cancer risk

(a) Top, P values from the GWAS for breast cancer (grey dots) and P values from SMR tests (diamonds). Bottom, P values eQTL data for SLC12A2 and CTC-228N24.3. Shown in a are all the SNPs available in the GWAS and eQTL data. (b) Effect sizes of the SNPs (used for the HEIDI test) from the GWAS against those from the eQTL data. The orange dashed lines represent the estimate of effect size of the MR association at the top cis-eQTL (rather than the regression line). Error bars are the standard errors of SNP effects.